PM
CLVS

Prosight Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Prosight Management’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-50,000
Closed -$2.64M – 36
2018
Q1 		$2.64M Buy
+50,000
New +$2.92M 1.66% 21

Other funds holding CLVS

PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Prosight Management's CLVS Position: Q4 2019 in Review

Prosight Management sold out of Clovis Oncology, Inc. (CLVS) in Q4 2019, closing a stake of 587,626 shares — an estimated $2.31M sold.

Prosight Management first reported a position in CLVS in Q4 2017 and held it in 6 quarters. The position peaked at $6.69M in Q2 2019. 147 funds tracked by Wall St. Rank hold CLVS as of Q4 2019.

  • Prosight Management reported no remaining Clovis Oncology, Inc. position as of Q4 2019 after selling out during the quarter.
  • Prosight Management sold 587,626 Clovis Oncology, Inc. shares in Q4 2019, an estimated $2.31M.
  • Prosight Management first reported a position in Clovis Oncology, Inc. in Q4 2017 and held it in 6 quarters.
  • Prosight Management's Clovis Oncology, Inc. position peaked at $6.69M in Q2 2019.
  • 147 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2019.

Based on Prosight Management's 13F filing for Q4 2019, filed 14 Feb 2020.